FindTrial
Sign In

The role of fecal calprotectin in the treatment of patients with clinically quiescent ulcerative colitis

The role of fecal calprotectin in the treatment of patients with clinically quiescent ulcerative colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021229
Enrollment
Unknown
Registered
2019-02-02
Start date
2019-02-18
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Intervention group:Increasing the dose of mesalamine according to fecal calprotectin levels
Control group:Maintaining current dosage of mesalamine

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with confirmed diagnosis of UC will be included if all of the following criteria are met: 1) Aged at least 18 years; 2) In clinical remission (Mayo clinical subscore: stool frequency = 1 and rectal bleeding =0) for at least 1 month; 3) On oral mesalamine =2g/day for at least 1 month; 4) Written informed consent obtained.

Exclusion criteria

Exclusion criteria: Patients will be excluded if: 1) Prior bowel operation (except for appendicectomy), or 2) Receive corticosteroids or immunosuppressants in the past 2 months, or 3) Allegic to mesalamine or intolerant to high dose of mesalamine, or 4) Pregnancy or lactating women.

Design outcomes

Primary

MeasureTime frame
Mucosal healing;—

Countries

China

Contacts

Public ContactHaiyun Shi

Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University

shihaiyun1016@gmail.com+86 010 63139842

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026